A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer

被引：0
|
作者：
Ai, X. [1 ]
Pan, Y. [2 ]
Shi, J. [3 ]
Yang, N. [4 ]
Liu, C. [5 ]
Zhou, J. [6 ]
Zhang, X. [7 ]
Dong, X. [8 ]
He, J. [9 ]
Li, X. [10 ,12 ]
Chen, G. [11 ]
Li, X. [10 ,12 ]
Zhang, H. [13 ]
Liao, W. [14 ]
Zhang, Y. [15 ]
Ma, Z. [16 ]
Zhang, B. [17 ]
Zhang, D. [17 ]
Lu, S. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[2] Anhui Prov Hosp, Dept Chemotherapy, Hefei, Anhui, Peoples R China
[3] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
[4] Hunan Canc Hosp, Lung & Gastrointestinal Oncol Dept, Changsha, Hunan, Peoples R China
[5] Xinjiang Med Univ, Canc Hosp, Dept Pulm Med, Urumqi, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China
[7] Nantong Tumor Hosp, Dept Med Oncol, Nantong, Peoples R China
[8] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China
[9] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China
[10] Liaoning Canc Hosp & Inst, Dept Thorac Med, Shenyang, Peoples R China
[11] Harbin Med Univ Canc Hosp, Dept Resp Med, Harbin, Heilongjiang, Peoples R China
[12] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China
[13] Tangdu Hosp, Dept Oncol, Xian, Shaanxi, Peoples R China
[14] Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[15] Zhejiang Canc Hosp, Dept Thorac Medial Oncol, Hangzhou, Zhejiang, Peoples R China
[16] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[17] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.371
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
377O
引用
收藏
页码：S1387 / S1387
页数：1
相关论文
共 50 条
  • [21] A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer
    Corr, Bradley
    Haggerty, Ashley
    Gysler, Stefan
    Taylor, Sarah
    Behbakht, Kian
    Alldredge, Jill
    Lefkowits, Carolyn
    Brubaker, Lindsay
    Bouts, Catherine
    Babayan, Lisa Marie
    Hopp, Samantha
    Hu, Junxiao
    Guntupalli, Saketh
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S63 - S63
  • [22] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial
    DeGregorio, Michael
    Soe, Lin
    Wolf, Michael
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 571 - 573
  • [23] Consolidative radiation therapy for extensive-stage small cell lung cancer
    Singer, Lisa
    Yom, Sue S.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (03) : 211 - 214
  • [24] A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer
    Xing, P.
    Zhou, S.
    Li, J.
    Yang, J.
    Yang, S.
    Tang, L.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S690 - S691
  • [25] Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study
    Kong, F.
    Wang, Z.
    Wang, N.
    Zhang, D.
    Liao, D.
    Zhang, J.
    Su, C.
    Jia, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S691 - S692
  • [26] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [27] Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
    Daniel, Davey
    Kuchava, Vladimer
    Bondarenko, Igor
    Ivashchuk, Oleksandr
    Reddy, Sreekanth
    Jaal, Jana
    Kudaba, Iveta
    Hart, Lowell
    Matitashvili, Amiran
    Pritchett, Yili
    Morris, Shannon R.
    Sorrentino, Jessica A.
    Antal, Joyce M.
    Goldschmidt, Jerome
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) : 2557 - 2570
  • [28] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
    Glisson, Bonnie
    Kazarnowicz, Andrzej
    Nackaerts, Kristiaan
    Orlov, Sergey
    Ramlau, Rodryg
    Besse, Benjamin
    Cobo Dols, Manuel
    Menon, Hari
    Paz-Ares Rodriguez, Luis
    Zhang, Yilong
    Zhu, Min
    Jiang, Yizhou
    Loh, Elwyn
    Gansert, Jennifer
    Dubey, Sarita
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S220 - S221
  • [29] Toripalimab For Extensive-Stage Small Cell Lung Cancer
    Daylan, Ayse Ece Cali
    Morgensztern, Daniel
    Waqar, Saiama N.
    JAMA ONCOLOGY, 2025, 11 (01) : 26 - 27
  • [30] Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    El Sayed, Rola
    Blais, Normand
    CURRENT ONCOLOGY, 2021, 28 (05) : 4093 - 4108
12345